Last $34.79 USD
Change Today +0.49 / 1.43%
Volume 536.1K
As of 5:20 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYGN) Snapshot

Open
$34.49
Previous Close
$34.30
Day High
$35.09
Day Low
$34.02
52 Week High
05/1/14 - $42.50
52 Week Low
11/17/14 - $31.56
Market Cap
2.5B
Average Volume 10 Days
738.8K
EPS TTM
$1.52
Shares Outstanding
73.0M
EX-Date
--
P/E TM
22.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYRIAD GENETICS INC (MYGN)

myriad genetics inc (MYGN) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYGN) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests in the United States and internationally. The company operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company’s molecular diagnostic tests are designed to analyze genes; diagnose diseases, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, including BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for hereditary melanoma. The company also provides myPath Melanoma diagnostic medicine test for melanoma; myPlan lung cancer, a prognostic medicine test for lung cancer; myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and Vectra DA, a personalized medicine test for rheumatoid arthritis. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

1,649 Employees
Last Reported Date: 08/13/14
Founded in 1991

myriad genetics inc (MYGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $997.0K
President of Myriad Genetic Laboratories
Total Annual Compensation: $568.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $734.0K
Chief Scientific Officer
Total Annual Compensation: $733.6K
Compensation as of Fiscal Year 2014.

myriad genetics inc (MYGN) Key Developments

Myriad Genetics, Inc. Publishes myPath Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics Inc. announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90% diagnostic accuracy.1 Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States. The published study describes the discovery, verification and clinical validation of the myPath Melanoma test, which was designed to differentiate benign moles from malignant melanoma. The myPath Melanoma test was developed using a verification cohort of 464 patient samples and was validated in a separate independent study with 437 patient samples from leading academic medical centers in the United States. In both the verification and validation studies, the myPath Melanoma test demonstrated a greater than 90% diagnostic accuracy, making it the most accurate molecular diagnostic test developed to date for melanoma. These clinical findings validate the performance, objectivity and reliability of the myPath Melanoma test for clinical use to improve the diagnosis of melanoma. About Myriad myPath Melanoma Testing: Myriad myPath Melanoma is a clinically validated gene expression test designed to differentiate malignant melanoma from benign nevi across all major melanoma subtypes.

GeneDx, Inc. Announces Settlement of Cancer Gene Testing Patent Dispute with Myriad Genetics

Sterne, Kessler, Goldstein & Fox P.L.L.C. announced that its client GeneDx, Inc. has settled its patent dispute with Myriad Genetics, Inc. The settlement resolves allegations of infringement on 16 patents involved in the diagnosis of hereditary cancer – 11 for genes related to breast cancer (BRCA1 and BRCA2) and five related to genes for colon cancer (MUTYH). The settlement clears litigation in the U.S. District Court for the District of Utah initiated by Myriad against GeneDx in October 2013, and follows previous settlements with seven other defendants. As part of the settlement the parties will move to terminate 13 inter partes review proceedings Sterne Kessler filed for GeneDx with the U.S. Patent and Trademark Office challenging the patentability of 13 patents owned, co-owned or licensed by Myriad. Under the settlement Myriad has given GeneDx a covenant not to sue over the patents asserted in the litigation. GeneDx will thus continue offering its services for breast cancer diagnostics which, individually or part of more comprehensive panels, all include testing for mutations in the BRCA1 and BRCA2 genes.

Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation

Quest Diagnostics announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation. Under the agreement, Quest Diagnostics and Myriad Genetics and its co-parties in the litigation, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche Inc. dismiss their lawsuits, claims, counterclaims and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation. Myriad has also provided Quest Diagnostics and its physician, hospital and other customers and business partners a covenant not to sue with respect to the patents at issue. Quest Diagnostics has the right to continue to offer its BRCAvantage and other BRCA-related testing services in their present form and to develop and provide additional genomic testing services in the future based on the portfolio of patents asserted by Myriad in this case.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $34.79 USD +0.49

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $27.76 USD +0.32
Alliance HealthCare Services Inc $21.34 USD -1.40
Bio-Reference Laboratories Inc $33.71 USD -2.80
Genomic Health Inc $32.33 USD +1.25
RadNet Inc $8.98 USD -0.06
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 23.7x
Price/Sales 3.4x
Price/Book 3.5x
Price/Cash Flow 22.1x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.